About Celemics
Celemics is a company based in Seoul (South Korea) founded in 2010.. The company has 42 employees as of December 31, 2024. Celemics operates in a competitive market with competitors including 23andMe, Guardant Health, Nanopore, Foundation Medicine and ArcherDX, among others.
- Headquarter Seoul, South Korea
- Employees 42 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Celemics, Inc.
-
Annual Revenue
$4.56 M (USD)2.15as on Dec 31, 2024
-
Net Profit
$8.32 M (USD)416.24as on Dec 31, 2024
-
EBITDA
$-752.65 K (USD)77.38as on Dec 31, 2024
-
Latest Funding Round
-
Investors
-
Employee Count
42
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Celemics
Celemics is a publicly listed company on the KRX with ticker symbol 331920 in South Korea, operating in the Electronic technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Funding Insights of Celemics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investments & Acquisitions by Celemics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Celemics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Celemics Comparisons
Competitors of Celemics
Celemics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as 23andMe, Guardant Health, Nanopore, Foundation Medicine and ArcherDX, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits
|
|
| domain | founded_year | HQ Location |
Digital sequencing technology for cancer detection is developed.
|
|
| domain | founded_year | HQ Location |
Nanopore-based electronic systems for single-molecule analysis are developed.
|
|
| domain | founded_year | HQ Location |
Genomics-based diagnostic tests for cancer are provided.
|
|
| domain | founded_year | HQ Location |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| domain | founded_year | HQ Location |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Celemics
Frequently Asked Questions about Celemics
When was Celemics founded?
Celemics was founded in 2010.
Where is Celemics located?
Celemics is headquartered in Seoul, South Korea.
How many employees does Celemics have?
As of Dec 31, 2024, the latest employee count at Celemics is 42.
What is the annual revenue of Celemics?
Annual revenue of Celemics is $4.56M as on Dec 31, 2024.
What does Celemics do?
Celemics was founded in 2010 and is based in Seoul, South Korea, within the biotechnology sector focused on genomics. Novel DNA Targeted Sequencing technology is utilized to enable personalized genome analysis for clients. Kits for various sequencing methods are provided, along with BRCA testing services that examine BRCA1 and BRCA2 genes for risks associated with breast, ovarian, colorectal, endometrial, lung, gastric, and other cancers.
Who are the top competitors of Celemics?
Celemics's top competitors include Guardant Health, Nanopore and 23andMe.
Is Celemics publicly traded?
Yes, Celemics is publicly traded on KRX under the ticker symbol 331920.
What is Celemics's ticker symbol?
The ticker symbol of Celemics is 331920 on KRX.